Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate

Artiva

Artiva

ARTV

0.00
  • Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis

     
  • Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases

     
  • Rheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trial

     
  • Safety and translational data support AlloNK's potential as an outpatient-administered, community-compatible deep B-cell depleting therapy

     
  • U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for the treatment of refractory rheumatoid arthritis

     
  • Artiva to host virtual webcast today at 8:15 am EDT, featuring Dr. Paul Emery, Arthritis UK professor of rheumatology at the University of Leeds
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.